Idelalisib (CAL-101, GS-1101)

製品コードS2226

Idelalisib (CAL-101, GS-1101)化学構造

分子量(MW):415.42

Idelalisib (CAL-101, GS-1101)は1種のセレクティブp110δ阻害剤です。無細胞試験で、IC50値は2.5 nMです。CAL-101 (Idelalisib, GS-1101)はp110δに表現する選択性はp110α/β/γに表現する選択性 より40-300倍が高くなって、C2β、hVPS34、DNA-PK とmTORに表現する選択性より400-4000倍が高くなります。

サイズ 価格(税別) 在庫  
JPY 25896.00 あり
JPY 19920.00 あり
JPY 78020.00 あり

文献中の使用例(29)

カスタマーフィードバック(4)

  • Invasive migration of RA FLS was analyzed through growth factor–reduced Matrigel-coated transwell inserts in the presence or absence of 1 µM INK007, 5 µM CAL-101, or 0.3 µM IPI-145, or 0.3 µM GDC-0941 inhibitors or DMSO. Cells were allowed to invade through Matrigel toward PDGF-BB (25 ng/ml) containing media for 24 h and were fixed and stained with Hemacolor staining kit.

    J Immunol, 2014, 192(5): 2063-70 . Idelalisib (CAL-101, GS-1101) purchased from Selleck.

    293T cells were transfected with HA-tagged Fbxo45. At 48 h after transfection, cells were treated with AKT inhibitor (CAL-101; 10 uM, 4 h), cell extracts from the cytoplasm or nuclei were subjected to IP with anti-HA resin followed by western blot analysis with indicated antibodies.

    Cell Death Differ 2014 21(10), 1535-45. Idelalisib (CAL-101, GS-1101) purchased from Selleck.

  • Isoform-selective PI3K inhibitors blocked PI3K signaling in corresponding Rh30-Myr-p110 cells. Rh30-Myr-p110s cells were cultured in serum-free medium for 12 h, and then exposed to CAL-101 at indicated concentrations for additional 1 h. The cells were collected to detect the level of phosphorylated and total Akt. β-Actin was served as loading control.

    Acta Pharmacol Sin 2013 34(9),1201-7. Idelalisib (CAL-101, GS-1101) purchased from Selleck.

    After starved in serum-free medium for 24 h,A549 cells incubated with the indicated concentrations of CAL-101 for 3 h,followed by 20-minute stimolation of 100ng/ml EGF.

    Dr. Zhang of Tianjin Medical University. Idelalisib (CAL-101, GS-1101) purchased from Selleck.

製品安全説明書

PI3K阻害剤の選択性比較

生物活性

製品説明 Idelalisib (CAL-101, GS-1101)は1種のセレクティブp110δ阻害剤です。無細胞試験で、IC50値は2.5 nMです。CAL-101 (Idelalisib, GS-1101)はp110δに表現する選択性はp110α/β/γに表現する選択性 より40-300倍が高くなって、C2β、hVPS34、DNA-PK とmTORに表現する選択性より400-4000倍が高くなります。
ターゲット
p110δ [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
2.5 nM 89 nM
体外試験

CAL-101 is not sensitive to other PI3K class I subunits including p110α, p110β, and p110γ. CAL-101 specifically blocks FcϵR1 p110δ-mediated CD63 expression with an EC50 of 8 nM in primary basophil. CAL-101 exhibits greater activity in B-cell acute lymphoblastic leukemia (B-ALL) and chronic lymphocytic leukemia (CLL) cells compared with acute myeloid leukemia (AML) and myeloproliferative neoplasm (MPN) cells. CAL-101 produces the reduction in pAktS473, pAktT308, and the downstream target S6 in SU-DHL-5, KARPAS-422 and CCRF-SB cells with EC50 of 0.1 to 1.0 μM. [1] CAL-101 induces selective cytotoxicity in CLL cells independent of IgVH mutational status or interphase cytogenetics, primarily through a caspase-dependent mechanism. CAL-101 induces cytotoxicity preferentially to CLL cells compared with normal B cells, without producing cytotoxicity in other hematopoietic cells, compared to LY294002. CAL-101 lacks direct cytotoxic potential to T cells and nature killer (NK) cells. CAL-101 can inhibit production of inflammatory cytokines, such as IL-6, IL-10, TNF-α, and IFN-γ, and activation-induced cytokines, such as CD40L. CAL-101 also antagonizes CD40L-mediated CLL cell survival. [2] CAL-101 induces an accumulation of cells in G1 and a decrease in the S-phase population in L1236 and L591 cells, which indicates CAL-101 as a novel strategy for the treatment of hodgkin lymphoma (HL). [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MEC1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoriSG1UVw>? M1L2WGlEPTB;MkCuOEDPxE1? NV\KflNTOjV7OUmzOVI>
CLL PBMCs MlHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHMTYpGTE2VTx?= NU[2W2RoUUN3ME2yMlkhdk1? M3rjeFI2QTF5Mk[3
U266 NIHRO|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLGOFAh|ryP MlvWOFghcA>? Mo\NO|kvPSViaX7obYJqfGmxbjDyZZRm M{PCSFI2OzN7M{Oy
K562 MVLGeY5kfGmxbjDBd5NigQ>? NXuyWFRlOSEQvF2= NILj[IU{KGh? MXnJcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25? NHHudHEzPTBzNEe3OS=>
K562 Mo[4SpVv[3Srb36gRZN{[Xl? NULJcFlQOSEQvF2= MXWzJIg> MVPJcohq[mm2aX;uJI9nKFB5MGO2T{BxcG:|cHjvdplt[XSrb36= NGTYWHIzPTBzNEe3OS=>
K562 NV3GNHZbTnWwY4Tpc44hSXO|YYm= M{HTZlEh|ryP NIT6c|Y{KGh? MYfJcohq[mm2aX;uJI9nKEeVS{OgdIhwe3Cqb4L5cIF1cW:w M2Ht[lI2ODF2N{e1
K562 NI\BfpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX2xJO69VQ>? M2rG[|czKGh? MofyTY5pcWKrdHnvckBw\iCycn;sbYZmemG2aX;u NYi3dXVEOjVyMUS3O|U>
Primary AML cell NELKVJNHfW6ldHnvckBCe3OjeR?= MlHrNUDPxE1? M3LJfFMhcA>? NFnEfHZKdmirYnn0bY9vKG:oIFHreEBxcG:|cHjvdplt[XSrb36= MoHvNlUxOTR5N{W=
Primary AML cell MYHGeY5kfGmxbjDBd5NigQ>? MUSxJO69VQ>? NYTRN3hDOyCq NHLmN5BKdmirYnn0bY9vKG:oIGC3NHM3UyCyaH;zdIhwenmuYYTpc44> NVHoenF[OjVyMUS3O|U>
Primary AML cell NV7oZ5VPTnWwY4Tpc44hSXO|YYm= MVixJO69VQ>? NVPjblNpOyCq Ml7STY5pcWKrdHnvckBw\iCJU1uzJJBpd3OyaH;yfYxifGmxbh?= M3PwOlI2ODF2N{e1
Primary AML cell MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\wNUDPxE1? MYSzJIg> NGjLZ4NUfXCycnXzd4lwdiCxZjDyVm5CKHO7boTo[ZNqew>? MlyyNlUxOTR5N{W=
Microglia MljGSpVv[3Srb36gRZN{[Xl? MVm1JO69VQ>? NUXWRZZROTBiaB?= NHzE[ZRFVVOR Mn:xSIVkemWjc3Wgc4YhXE6IYTDz[YNz\XSrb36g[pJwdSCOUGOtd5RqdXWuYYTl[EAheDFzMN80SFkyOEFxREmxNGEhdWmlcn;ncIli MViyOFYzPTZ6NB?=
Primary CLL cell Mn\XSpVv[3Srb36gRZN{[Xl? MWmxJO69VQ>? M13KVVE2KG2rbh?= MkHSSG1UVw>? NXrMO3M4SmyxY3vzJGJEWi2rbnT1Z4VlKEyFUEGgd4VzcW6nLUWgZYN1cX[jdHnvci=> NWrkXmJ5OjRyMEmyN|M>
JEKO-1 NUfOSYR4TnWwY4Tpc44hSXO|YYm= NELpWWYyKM7:TR?= MmDlO|IhcA>? M1;Gd2lvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbjDpckBK\01vc4TpcZVt[XSnZDDKSWtQNTF? M1jlWlI{OzRzNUSx
Granta-519 M2\oTGZ2dmO2aX;uJGF{e2G7 NEnU[poyKM7:TR?= M2DweFIhcA>? M4P6cWlvcGmkaYTpc44hd2ZiQXv0LJQ{ODhrIIDoc5NxcG:{eXzheIlwdg>? MofKNlM{PDF3NEG=
Granta-519 NFjoPXpHfW6ldHnvckBCe3OjeR?= M{LhUVEh|ryP MlXENkBp Mn;DTY5pcWKrdHnvckBw\iCDa4Sod|Q4OylicHjvd5Bpd3K7bHH0bY9v MVWyN|M1OTV2MR?=
JEKO-1 NITmSZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfZ[pJROTBizszN M4DYNlczKGh? MmP4TY5pcWKrdHnvckBw\iCycn;sbYZmemG2aX;uJJNtcWeqdHz5 M4XQZlI{OzRzNUSx
JEKO-1 NYTEeoFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDwSoJUPSEQvF2= NEDJbnU4OiCq M3\s[IRw\XNibn;0JIlv\HWlZTDj[YxtKGO7Y3zlJIFzemW|dDDvdkBieG:ydH;zbZM> M4\aPFI{Pjd4MkKw
MAVER-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIT5cVM2KM7:TR?= MWe3NkBp NV60OYpy\G:nczDuc5QhcW6mdXPlJINmdGxiY4njcIUh[XK{ZYP0JI9zKGGyb4D0c5Nqew>? M3PZPFI{Pjd4MkKw
MINO MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX:1JO69VQ>? M3;XRlczKGh? MULkc4V{KG6xdDDpcoR2[2ViY3XscEBkgWOuZTDhdpJme3Rib4KgZZBweHSxc3nz NGfZUpczOzZ5NkKyNC=>
SP53 M3jhdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUCwMlEh|ryP NUjTZ2V[PzJiaB?= M3rk[IRw\XNibn;0JIlv\HWlZTDj[YxtKGO7Y3zlJIFzemW|dDDvdkBieG:ydH;zbZM> MkjINlM3PzZ{MkC=
HH M37Eb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzhUnRbOTBizszN MU[3NkBp NHX2c|FFVVOR MYLJcoR2[3Srb36gc4Yh[XCxcITvd4l{KHOuaXfoeIx6 M1PQflIzQDBzOUW5
Myla NGfNNnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzGRoZbOTBizszN NV;2TWR6PzJiaB?= M1XuV2ROW09? NIj4[Gxld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nz NIC0doIzOjhyMUm1PS=>
SR786 NF;Sb2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUGxNEDPxE1? MX[3NkBp MV7EUXNQ M{nkOoRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYO= M3PTXFIzQDBzOUW5
HuT78 MoPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVyxNEDPxE1? NETKdpI4OiCq NWTSUmFpTE2VTx?= NFr2ZVFld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nz Ml3ONlI5ODF7NUm=
MJ MoTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrZNVAh|ryP MnjPO|IhcA>? Ml\sSG1UVw>? NHK3Nplld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nz MVyyNlgxOTl3OR?=
DERL7 NUi3fItZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXWxNEDPxE1? MX63NkBp NYi0eHVOTE2VTx?= NYTuOY93\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppdy=> NHrmfGwzOjhyMUm1PS=>
L1236 MVHGeY5kfGmxbjDBd5NigQ>? NF3MOmYyOCEQvF2= NU\5VJVUOiCq MUDJcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25? M2j0WlIzOjFyOEe3
L428 MnrWSpVv[3Srb36gRZN{[Xl? NVvlS3NWOTBizszN MoLaNkBp MmfJTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:w M2TtTVIzOjFyOEe3
L591 MlrsSpVv[3Srb36gRZN{[Xl? NVXaXYZJOTBizszN M3LOfFIhcA>? M{fNR2lvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbh?= M4HiTFIzOjFyOEe3
KMH-2 MXvGeY5kfGmxbjDBd5NigQ>? NV3YSnVNOTBizszN MnPkNkBp M{TmRmlvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbh?= NX\qNWtCOjJ{MUC4O|c>
L1236 NFLJTnBHfW6ldHnvckBCe3OjeR?= Ml3SOUDPxE1? M1PmNlI1KGh? M3zKSWJtd2OtczDz[YNz\XSrb36gc4YhfGinIFPDUFU> MlLqNlIzOTB6N{e=
L591 M1PMN2Z2dmO2aX;uJGF{e2G7 M1Tud|Uh|ryP M16zNFI1KGh? M4XPeGJtd2OtczDz[YNz\XSrb36gc4YhfGinIFPDUFU> NH;COnEzOjJzMEi3Oy=>
L1236 MVPBdI9xfG:|aYOgRZN{[Xl? MWC1JO69VQ>? M4fKTlI1KGh? MkHLTY5lfWO2aX;uJI9nKGGyb4D0c5Nqew>? NFv3fFAzOjJzMEi3Oy=>
L591 Mlu0RZBweHSxc3nzJGF{e2G7 NXu3VIRtPSEQvF2= M2X5WlI1KGh? M2jVR2lv\HWldHnvckBw\iCjcH;weI9{cXN? NHW0cXAzOjJzMEi3Oy=>
U-87MG MVXGeY5kfGmxbjDBd5NigQ>? M1PoblExOCCwTR?= NUnOZnF2OjRiaB?= NX3O[|NVTE2VTx?= M2jnbmlvcGmkaYTpc44hd2ZiIHPlcIwhdWmpcnH0bY9v MXOyNlA4QTZyOR?=
SW1783 NFzOcWxHfW6ldHnvckBCe3OjeR?= MV:xNFAhdk1? MVOyOEBp MYTEUXNQ NVnjfXhQUW6qaXLpeIlwdiCxZjCgZ4VtdCCvaXfyZZRqd25? Mo\iNlIxPzl4MEm=
U-87MG NHf0c5JHfW6ldHnvckBCe3OjeR?= MVK1JO69VQ>? MUiyOEBp NGXGUZFFVVOR NYfCcVk4UW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;uJJN2[nO2YX70bYFtdHl? NVrZV2NLOjJyN{m2NFk>
SW1783 NF3kXZNHfW6ldHnvckBCe3OjeR?= MVO1JO69VQ>? M3nrcVI1KGh? NXfpNVE1TE2VTx?= MmjKTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIIP1ZpN1[W62aXHscJk> NYnIXGQ2OjJyN{m2NFk>
U-373MG M4fNRmZ2dmO2aX;uJGF{e2G7 MnzPOUDPxE1? NFrmcZMzPCCq M1rpb2ROW09? NXviZmhYUW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;uJJN2[nO2YX70bYFtdHl? NYLoUGdyOjJyN{m2NFk>
SK-MG3 M2nafGZ2dmO2aX;uJGF{e2G7 NWDXPZc2PSEQvF2= M4DLNlI1KGh? M1PlNGROW09? NIPabXZKdmirYnn0bY9vKG:oIFHreEBxcG:|cHjvdplt[XSrb36gd5Vje3SjboTpZYxtgQ>? NE[zb2MzOjB5OU[wPS=>
SU-DHL-5 MYnGeY5kfGmxbjDBd5NigQ>? MY[xJO69VQ>? NYXvNmpQOjRiaB?= NGjpU5NFVVOR NInUcoRKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m| MUCyNFk2QTZyNh?=
WSU-NHL NXmzNJBTTnWwY4Tpc44hSXO|YYm= MnPzNUDPxE1? M3XOUFI1KGh? M3zxZ2ROW09? NEjYWVFKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m| NIjSTWQzODl3OU[wOi=>
CCRF-SB MVLGeY5kfGmxbjDBd5NigQ>? MmL0NUDPxE1? NFzYd44zPCCq MVrEUXNQ Mo\STY5lfWO2aX;uJI9nKGGyb4D0c5Nqew>? MWiyNFk2QTZyNh?=
INA-6 Ml\kSpVv[3Srb36gRZN{[Xl? MlPEOUDPxE1? NIj5dIY3KGh? MlLnTY5pcWKrdHnvckBw\iCSSUPLM2FsfCCjbnSgSXJMKHCjdHj3ZZk> NVH5XIhzOjB3MEWxOVg>
LB M2LSTmZ2dmO2aX;uJGF{e2G7 MVG1JO69VQ>? NETlRYc3KGh? M4S0[GlvcGmkaYTpc44hd2ZiUFm0T{9Cc3RiYX7kJGVTUyCyYYToe4F6 NX3OU|BVOjB3MEWxOVg>

多くの細胞株試験データを見る場合、クリックしてください

お薦めの試験操作(参考用のみ)

キナーゼ試験:[2]
+ 展開

PI3K assay:

PI3K assay is preformed on whole-cell lysates from CLL or normal B cells. A PI3K ELISA assay is performed. Briefly, whole-cell extracts are added to a mixture of PI(4,5)P2 substrate and reaction buffer containing adenosine triphosphate (ATP) and allowed to incubate at room temperature. The reaction is stopped by adding PI(3,4,5)P3 detector mixed with EDTA (ethylenediaminetetraacetic acid) and allowed to incubate at room temperature for 1 hour. After this time, the mixture is transferred from each well to a PI3K ELISA plate and allowed to incubate 1 hour. Plates are washed and then incubated with secondary detector for 30 minutes. Plates are washed again, and 3,3′,5,5′-tetramethylbenzidine solution is added for 5 minutes at which time H2SO4 is added to stop all reactions. Plates are read at 450 nm on a Labsystems 96-well plate reader.
細胞試験: [2]
+ 展開
  • 細胞株: CLL B cells or healthy volunteer T cells or NK cells
  • 濃度: 0.01-100 μM
  • 反応時間: 48 hours
  • 実験の流れ: MTT assays are performed to determine cytotoxicity. 1 × 105 cells are incubated with CAL-101. MTT reagent is then added, and plates are incubated for an additional 20 hours before washing with protamine sulfate in phosphate-buffered saline. DMSO is added, and absorbance is measured by spectrophotometry at 540 nm in a Labsystems plate reader. Cell viability is also measured at various time points with the use of annexin/PI flow cytometry. Data are analyzed. At least 104 cells are counted for each sample. Results are expressed as the percentage of total positive cells over untreated control. Experiments examining caspase-dependent apoptosis included the addition of 100 μM Z-VAD. Experiments examining survival signals include the addition of 1 μg/mL CD40L, 800 U/mL IL-4, 50 ng/mL BAFF, 20 ng/mL TNF-α, or coculturing on fibronectin or stromal (HS-5 cell line) coated plates. Stromal coculture is done by plating a 75-cm2 flask (80%-100% confluent) per 6-well plate 24 hours before the addition of CLL cells.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 83 mg/mL (199.79 mM) warming
Ethanol 23 mg/mL (55.36 mM)
Water Insoluble
体内 順序で溶剤を入れること:
30% PEG 400 (dissolve first)+0.5% Tween 80+5% Propylene glycol
30mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 415.42
化学式

C22H18FN7O

CAS No. 870281-82-6
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02457598 Recruiting B-cell Malignancies Gilead Sciences June 30, 2015 Phase 1
NCT02962401 Not yet recruiting Waldenstrom Macroglobulinemia French Innovative Leukemia Organisation January 2017 Phase 2
NCT02928510 Not yet recruiting Absence of Signs or Symptoms|B-Cell Non-Hodgkin Lymphoma|Digestive System Signs and Symptoms|Indolent Adult Non-Hodgkin Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Indolent Adult Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma Jonsson Comprehensive Cancer Center|Gilead Sciences|National Cancer Institute (NCI) January 2017 --
NCT02968563 Recruiting Chronic Lymphocytic Leukemia Gilead Sciences|German CLL Study Group December 2016 Phase 2
NCT02639910 Recruiting Leukemia, Lymphocytic, Chronic, B-Cell|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma MorphoSys AG November 2016 Phase 2
NCT02970318 Recruiting Chronic Lymphocytic Leukemia Acerta Pharma BV September 2016 Phase 3

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    What is the recommended dose of CAL-101 and the route of administration for mouse studies?

  • 回答:

    According to the following paper, S2226 can be used by I.V. administration at the concentration of 40 mg/kg. http://www.ncbi.nlm.nih.gov.ezproxy.liv.ac.uk/pubmed/?term=PI3K%CE%B4+inhibition+reduces+TNF+secretion+and+neuroinflammation+in+a+mouse+cerebral+stroke+model

PI3K信号経路図

PI3K Inhibitors with Unique Features

相関PI3K製品

Tags: Idelalisib (CAL-101, GS-1101)を買う | Idelalisib (CAL-101, GS-1101) ic50 | Idelalisib (CAL-101, GS-1101)供給者 | Idelalisib (CAL-101, GS-1101)を購入する | Idelalisib (CAL-101, GS-1101)費用 | Idelalisib (CAL-101, GS-1101)生産者 | オーダーIdelalisib (CAL-101, GS-1101) | Idelalisib (CAL-101, GS-1101)化学構造 | Idelalisib (CAL-101, GS-1101)分子量 | Idelalisib (CAL-101, GS-1101)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID